RCUS Q4 2020 Earnings — Arcus Biosciences, Inc. Revenue & Financial Results | Market Cap Arena

RCUSArcus Biosciences, Inc.

$2B

Q4 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$9M-2.7% YoY

Gross Profit

$9M100.0% margin

Operating Income

-$52M-548.2% margin

Net Income

-$52M-546.6% margin

EPS (Diluted)

$-0.82

QoQ Revenue Growth

-85.3%

Cash Flow

Operating Cash Flow

-$50M

Free Cash Flow

-$51M

Stock-Based Comp.

$8M

Balance Sheet

Total Assets

$772M

Total Liabilities

$270M

Stockholders' Equity

$502M

Cash & Equivalents

$173M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$9M	$10M	-2.7%
Gross Profit	$9M	$10M	-2.7%
Operating Income	-$52M	-$18M	-196.8%
Net Income	-$52M	-$17M	-212.4%

Revenue Segments

Gilead Access Rights

$8M82%

Taiho Collaboration Agreement

$2M18%